Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 81.45

-1.6%

Dec 29 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (362)	8/28/2003 11:18:59 AM
From: Jibacoa	Read Replies (1) of 3722

MAXM Opened with a small up-gap today. It needs to close above 6.60 before it can retest the resistance at the 6.70 to 6.80 level.<g> 6.70 was the intra-day H on June 12, the day it announced Ceplene's Phase III results in patients with metastatic melanoma. Ceplene, the histamine based product,is supposed to act by protecting cells against the deleterious effects of the high oxygen radicals, and the company is planning to file an application for approval to market Ceplene for the treatment of advanced metastatic melanoma in Europe in late 2003. biz.yahoo.com Although MAXM's revenues have increased lately, the net loss has also increased, apparently due to "increased research and development expenses". At any rate, the company still has about $3.50 in cash/share, so there is a good possibility that it may not need extra financing in spite of their increased reported loss, provided that they will be able to start marketing Ceplene in Europe next year.<g> siliconinvestor.com siliconinvestor.com From a longer perspective the chart looks interesting.<g> siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next